INVESTOR.IRONWOODPHARMA.COM

Ironwood Pharmaceuticals, Inc. - Investor Relations

At Ironwood, were focused on delivering differentiated medicines to patients. If we do this efficiently and effectively, we hope to generate outstanding returns for our shareholders, inspiring their continued support so that we can create more medicines and build an enduring pharmaceutical company. These are not small goals, but we believe they represent the best way to maximize long-term value for both patients and shareholders. NASDAQ: IRWD $15.43 0.23. Volume: 942,811 Change: 1.513%. Feb 22, 2018.

http://investor.ironwoodpharma.com/

OVERVIEW OF investor.ironwoodpharma.com

TRAFFIC RANK

>1,000,000

REVIEWS

0

PAGES IN THIS WEBSITE

20

LINKS TO THIS WEBSITE

CONTACTS

ADDRESSES

SOCIAL LINKS

ONLINE SINCE

WEBSITE DETAILS

SEO

PAGES

SIMILAR SITES

TRAFFIC RANK FOR INVESTOR.IRONWOODPHARMA.COM

TODAY'S RATING

>1,000,000

TRAFFIC RANK - AVERAGE PER MONTH

BEST MONTH

August

AVERAGE PER DAY Of THE WEEK

HIGHEST TRAFFIC ON

Saturday

TRAFFIC BY CITY

Sign up

CUSTOMER REVIEWS

Average Rating: 4.1 out of 5 with 10 reviews

5 star

3

4 star

5

3 star

2

2 star

0

1 star

0

Hey there! Start your review of investor.ironwoodpharma.com

AVERAGE USER RATING

Write a Review

WEBSITE PREVIEW

LOAD TIME

0.5 seconds

FAVICON PREVIEW

16x16

CONTACTS AT INVESTOR.IRONWOODPHARMA.COM

ADD CONTACT

Login

TO VIEW CONTACTS

Remove Contacts

FOR PRIVACY ISSUES

CONTENT

PAGES IN
THIS WEBSITE

20

SSL

EXTERNAL LINKS

82

SITE IP

206.200.251.19

LOAD TIME

0.483 sec

SCORE

6.2

PAGE TITLE

Ironwood Pharmaceuticals, Inc. - Investor Relations | investor.ironwoodpharma.com Reviews

<META> DESCRIPTION

At Ironwood, were focused on delivering differentiated medicines to patients. If we do this efficiently and effectively, we hope to generate outstanding returns for our shareholders, inspiring their continued support so that we can create more medicines and build an enduring pharmaceutical company. These are not small goals, but we believe they represent the best way to maximize long-term value for both patients and shareholders. NASDAQ: IRWD $15.43 0.23. Volume: 942,811 Change: 1.513%. Feb 22, 2018.

<META> KEYWORDS

1 overview

2 business principles

3 events

4 corporate governance

5 management team

6 board of directors

7 committees

8 contact the board

9 financial information

10 sec filings

CONTENT

Page content here

KEYWORDS ON PAGE

overview,business principles,events,corporate governance,management team,board of directors,committees,contact the board,financial information,sec filings,annual reports,quarterly results,key ratios,stock information,historic stock lookup,analyst coverage

POWERED BY

ASP.NET

CONTENT-TYPE

utf-8

GOOGLE PREVIEW

Ironwood Pharmaceuticals, Inc. - Investor Relations | investor.ironwoodpharma.com Reviews

https://investor.ironwoodpharma.com

At Ironwood, were focused on delivering differentiated medicines to patients. If we do this efficiently and effectively, we hope to generate outstanding returns for our shareholders, inspiring their continued support so that we can create more medicines and build an enduring pharmaceutical company. These are not small goals, but we believe they represent the best way to maximize long-term value for both patients and shareholders. NASDAQ: IRWD $15.43 0.23. Volume: 942,811 Change: 1.513%. Feb 22, 2018.

INTERNAL PAGES

investor.ironwoodpharma.com

1

Ironwood Pharmaceuticals, Inc. - Annual Reports

http://investor.ironwoodpharma.com/annuals.cfm

Add file to Briefcase. You are now leaving ironwoodpharma.com. This link will take you to. A website to which our privacy policy. Does not apply. You are solely. Responsible for your interactions with that website. Cambridge, MA 02142. Tel 617.621.7722. Fax 617.494.0480. Is a registered trademark of Ironwood Pharmaceuticals, Inc. Privacy Policy.

2

Ironwood Pharmaceuticals, Inc. - Owner-related Business Principles

http://investor.ironwoodpharma.com/owner.cfm

Show / hide all. 1 Ironwood's stockholders own the business; all of our employees work for them. Each of our employees also has equity in the business, aligning their interests with their fellow stockholders. As employees and co-owners of Ironwood, our management and employee team seek to effectively allocate scarce stockholder capital to maximize the average annual growth of per share value. 2 We believe we can best maximize long-term stockholder value by building a great pharmaceutical franchise. Our d...

3

Ironwood Pharmaceuticals, Inc. - Events

http://investor.ironwoodpharma.com/events.cfm

2022 Convertible Senior Notes Financial Statement Presentation. P&L Presentation of LINZESS. Details on upcoming events are not yet available. Aug 4, 2016. Ironwood Pharmaceuticals 2Q 2016 Investor Update Conference Call. Jun 10, 2016. Jefferies 2016 Healthcare Conference. Jun 7, 2016. Goldman Sachs 37th Annual Global Healthcare Conference. Jun 1, 2016. Ironwood Pharmaceuticals 2016 Annual Meeting. May 25, 2016. 2016 UBS Global Healthcare Conference. May 9, 2016. Apr 26, 2016. Feb 18, 2016. Nov 3, 2015.

4

Ironwood Pharmaceuticals, Inc. - Quarterly Results

http://investor.ironwoodpharma.com/results.cfm

Show / hide all. Ironwood Pharmaceuticals Provides Second Quarter 2016 Investor Update. Ironwood Pharmaceuticals 2Q 2016 Investor Update Conference Call. Ironwood Pharmaceuticals Provides First Quarter 2016 Investor Update. Ironwood Pharmaceuticals 1Q 2016 Investor Update Conference Call. Ironwood Pharmaceuticals Provides Fourth Quarter and Full Year 2015 Investor Update. Ironwood Pharmaceuticals 4Q 2015 Investor Update Conference Call. Ironwood Pharmaceuticals Provides Third Quarter 2015 Investor Update.

5

Ironwood Pharmaceuticals, Inc. - Historic Stock Lookup

http://investor.ironwoodpharma.com/stocklookup.cfm

Week of August 22, 2016. Aug 22, 2016. Aug 23, 2016. Aug 24, 2016. Aug 25, 2016. Aug 26, 2016. Year End Stock Prices. The historical stock information provided is for informational purposes only and is not intended for trading purposes. The historical stock information is provided by Mergent, a third party service, and Ironwood Pharmaceuticals, Inc. does not maintain or provide information directly to this service. Prices display split-adjusted cost basis per share on that date. Cambridge, MA 02142.

UPGRADE TO PREMIUM TO VIEW 15 MORE

TOTAL PAGES IN THIS WEBSITE

20

LINKS TO THIS WEBSITE

ironwoodpharma.com

Ironwood Pharmaceuticals | Collaborate

http://www.ironwoodpharma.com/collaborate

Skip to main content. You are now leaving ironwoodpharma.com. This link will take you to. A website to which our privacy policy. Does not apply. You are solely. Responsible for your interactions with that website. At Ironwood, we’re focused on three goals:. Transforming knowledge into medicines that make a difference for patients, creating value that will inspire the continued support of our fellow shareholders, and building a team that passionately pursues excellence. How we seek the best.

ironwoodpharma.com

Ironwood Pharmaceuticals | Our Expertise

http://www.ironwoodpharma.com/our-expertise

Skip to main content. You are now leaving ironwoodpharma.com. This link will take you to. A website to which our privacy policy. Does not apply. You are solely. Responsible for your interactions with that website. The Making of Medicines. At Ironwood, this team includes:. Cambridge, MA 02142. Tel 617.621.7722. Fax 617.494.0480.

ironwoodpharma.com

Ironwood Pharmaceuticals | Pharmaceutical Advisory Committee

http://www.ironwoodpharma.com/pharmaceutical-advisory-committee

Skip to main content. You are now leaving ironwoodpharma.com. This link will take you to. A website to which our privacy policy. Does not apply. You are solely. Responsible for your interactions with that website. BENJAMIN CRAVATT, PH.D. The Scripps Research Institute. PERRY HALUSHKA, PH.D., M.D. Medical University of South Carolina. LAWRENCE OLANOFF, M.D., Ph.D. Medical University of South Carolina. CHRISTOPHER WALSH, PH.D. Cambridge, MA 02142. Tel 617.621.7722. Fax 617.494.0480.

ironwoodpharma.com

Ironwood Pharmaceuticals | Join Us

http://www.ironwoodpharma.com/join-us

Skip to main content. You are now leaving ironwoodpharma.com. This link will take you to. A website to which our privacy policy. Does not apply. You are solely. Responsible for your interactions with that website. Learn about Ironwood's founding and our evolution into the commercial biotechnology company we are today. Read about our culture of innovation. Careers, not jobs. Careers, not jobs. THE ART AND SCIENCE OF MAKING MEDICINES. How are we connected? Accounting Intern ». HQ: Cambridge Dept: Finance.

ironwoodpharma.com

Ironwood Pharmaceuticals | About Us

http://www.ironwoodpharma.com/about-us

Skip to main content. You are now leaving ironwoodpharma.com. This link will take you to. A website to which our privacy policy. Does not apply. You are solely. Responsible for your interactions with that website. Learn about Ironwood's founding and our evolution into the commercial biotechnology company we are today. THE ART AND SCIENCE OF MAKING MEDICINES. Ironwood is committed to the art and science of. Patient needs shape our business. Shareholders shape our success. Being a shareholder of Ironwood i...

ironwoodpharma.com

Ironwood Pharmaceuticals | Global Strategy

http://www.ironwoodpharma.com/global-strategy

Skip to main content. You are now leaving ironwoodpharma.com. This link will take you to. A website to which our privacy policy. Does not apply. You are solely. Responsible for your interactions with that website. Bringing Linaclotide to Patients Around the World. LINZESS * available in U.S. through 50/50 collaboration. Constella available in certain European countries through partnership. Click here for full Prescribing Information including BOXED WARNING ». Learn more about LINZESS ».

ironwoodpharma.com

Ironwood Pharmaceuticals

http://www.ironwoodpharma.com/index.php

Skip to main content. You are now leaving ironwoodpharma.com. This link will take you to. A website to which our privacy policy. Does not apply. You are solely. Responsible for your interactions with that website. THE ART AND SCIENCE OF MAKING MEDICINES. We’re focused on three goals: transforming knowledge into medicines that make a. Difference for patients, creating value that will inspire the continued support of our. Fellow shareholders, and building a team that passionately pursues excellence.

ironwoodpharma.com

Ironwood Pharmaceuticals | Founders

http://www.ironwoodpharma.com/founders

Skip to main content. You are now leaving ironwoodpharma.com. This link will take you to. A website to which our privacy policy. Does not apply. You are solely. Responsible for your interactions with that website. Serves as our CEO, Brian Cali. Serves as our senior vice president of preclinical R&D, and Todd Milne serves as our vice president leading sGC R&D. Co-founders: Todd Milne, Peter Hecht, and Brian Cali. Cambridge, MA 02142. Tel 617.621.7722. Fax 617.494.0480.

UPGRADE TO PREMIUM TO VIEW 74 MORE

TOTAL LINKS TO THIS WEBSITE

82

SOCIAL ENGAGEMENT

share.php

ironwoodpharma

OTHER SITES

investor.ipgphotonics.com

IPG Photonics

Skip to main content. Consumer Electronics and Appliances. Entertainment and Projection Display. Heavy Industry and Transport. Consumer Electronics and Appliances. Entertainment and Projection Display. Heavy Industry and Transport. IPG PHOTONICS ANNOUNCES 40% REVENUE GROWTH FOR FULL YEAR 2017. Fourth Quarter Revenue and Operating Income Increase 29% and 41%, Respectively. Charges Related to U.S. Tax Cuts and Jobs Act Reduce Earnings Per Diluted Share by $0.90. Fourth Quarter 2017 Earnings Press Release.

investor.iress.co.za

IRESSInvestor Log On

You must have cookies turned on to use this application. Please enter your username and password.

investor.irf.com

Investor Relations

International Rectifier is a pioneer and world leader in advanced power management technology, from analog and mixed signal ICs to advanced circuit devices, power systems, and components. Technological breakthroughs from IR are setting the pace for innovation in the electronics we all rely upon each day. Inside our factories and automobiles, at our homes and offices, and orbiting our world, IR’s power management technology is enabling today’s leading-edge computers, . Sign Up For Investor Updates.

investor.iridium.com

Investor Relations - Iridium Communications Inc.

Internet of Things (IoT). Send a Satellite Message. Test Your Satellite Phone. The world's only truly global mobile satellite communications company. We are a diverse, global communications provider of mobile voice and data services via 66 in–orbit satellites. We compete in attractive and growing markets with favorable competitive dynamics and high barriers to entry. Our key sectors include land/mobile handsets, machine–to–machine (M2M), maritime, aviation and the U.S. Government. Day High: 11.40. Iridiu...

investor.irobot.com

Investors | IROBOT CORPORATION

Skip to main navigation. News, Reviews and Awards. What Sets Us Apart. For more than 25 years, iRobot has designed and built robots that empower people to do more both inside and outside of the home. Since the introduction of its Roomba Ò. In 2017, iRobot generated $884 million in revenue and employed more than 900 of the robot industry’s top professionals. iRobot stock trades on the NASDAQ stock market under the ticker symbol IRBT. There are currently no events to display. BEDFORD, Mass. , Feb. ...BEDFO...

investor.ironwoodpharma.com

Ironwood Pharmaceuticals, Inc. - Investor Relations

At Ironwood, were focused on delivering differentiated medicines to patients. If we do this efficiently and effectively, we hope to generate outstanding returns for our shareholders, inspiring their continued support so that we can create more medicines and build an enduring pharmaceutical company. These are not small goals, but we believe they represent the best way to maximize long-term value for both patients and shareholders. NASDAQ: IRWD $15.43 0.23. Volume: 942,811 Change: 1.513%. Feb 22, 2018.

investor.isaria.ag

ISARIA Wohnbau München – Wohnungen so schön wie München

KAPITALERHÖHUNG 2016 (available in German only). ISARIA Wohnbau AG is already one of the established large project development companies for housing construction in Germany. Our goal is to strengthen our position in the market sustainably until 2020. For this purpose, the company has secured private equity investor Lone Star as financially strong partner who supports the continued implementation of the Company's growth strategy. ISARIA Wohnbau AG: ISARIA Wohnbau AG announces delisting.

investor.itc-holdings.com

Investor Overview - ITC Holdings Corp.

Fixed Income Investor FAQs. Annual Report and Proxy. Dividend and Split Information. Direct Stock Purchase and Dividend Reinvestment Plan. Michigan Electric Transmission Company, ITC Midwest and ITC Great Plains. Raquo; Latest Proxy Statement. Raquo; 2014 Online Annual Report. Raquo; 2014 Annual Report. Raquo; Investor Fact Sheet. Day High: 34.73. Day Low: 33.57. Aug 7, 2015. Delayed 20 min., by eSignal. Jul 30, 2015. ITC Reports Continued Strong Growth for Second Quarter and Year-to-Date 2015 Results.

investor.itg.com

Investor Relations | ITG

ITG Execution Management Systems. ITG Order Management Systems. Code of Business Conduct and Ethics. Earnings and Trading Volumes. Q2 2015 Investment Technology Group, Inc. Earnings Conference Call. ITG Announces Management Changes. Data collected 08/01/15 - 08/08/15. Q2 2015 Investment Technology Group, Inc. Earnings Conference Call. August 04, 2015. 160;at 8:30 am ET. Q2 2015 Investment Technology Group, Inc. Earnings Conference Call. Tuesday, August 4, 2015 . 8:30 am ET . Click here for webcast.

investor.itw.com

Investor Information | Investor Relations | ITW

Skip to primary content. Skip to secondary content. Test and Measurement and Electronics. Students and Recent Graduates. Online Proxy / Voting. ITW Board of Directors Approves 13.4 Percent Dividend Increase for Third Quarter 2015. ITW Reports Second Quarter 2015 Financial Results. ITW Announces Conference Call Information for the 2015 Second Quarter. ITW Announces Plans to Webcast Presentation for Deutsche Bank Global Industrials Conference. View all News Releases. 160; 0.08. Volume: 1,342,292.

investor.iwebslog.info

This Web page parked FREE courtesy of Iwebslog. Search for domains similar to. Is this your domain? Let's turn it into a website! Would you like to buy this. Find Your Own Domain Name. See our full line of products. Easily Build Your Professional Website. As low as $6.28/mo. Call us any time day or night (480) 624-2500.